• Overview
  • Eligibility
  • More info
  • Locations

Phase II Study of Herceptin (Recombinant Humanized Anti-p185HER2 Monoclonal Antibody) for the Treatment of Androgen Independent Prostate Cancer (NCT00003740)

National Cancer Institute (NCI)
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of trastuzumab in treating patients who have prostate cancer that has not responded to hormone therapy.
  • Biological: trastuzumab
    Ages eligible for Study
    18 Years and older
    Genders eligible for Study
    Male
    Accepts Healthy Volunteers
    No
    OBJECTIVES: I. Assess the activity of trastuzumab (Herceptin) in patients with progressive androgen dependent and independent prostate cancer. II. Study HER2 status by immunohistochemistry on prostate cancer biopsy samples. III. Study associations between HER2 protein expression on tumor cells and post-therapy changes in PSA in this patient population.

    OUTLINE: Patients receive trastuzumab IV over 30 or 90 minutes once a week. Treatment continues for a maximum of 24 weeks in the absence of unacceptable toxicity or disease progression. Patients are followed for time to progression.

    PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study within 6-9 months.

    1 locations

    United States (1)
    • Memorial Sloan-Kettering Cancer Center
      New York, New York, United States, 10021
    Status:
    completed
    Type:
    Interventional
    Phase:
    Start:
    30 September, 1998
    Updated:
    19 June, 2013
    Participants:
    0
    A girl giving information about available additional trials.

    FindMeCure helps you find, understand and join clinical trials from all over the world.

    There are more clinical trials for your condition!